Navigation Links
OrPro Therapeutics Receives NIH Grant Award to Advance Development of Recombinant Thioredoxin for Treatment of Cystic Fibrosis

SAN DIEGO, July 31, 2012 /PRNewswire/ -- OrPro Therapeutics, Inc. today announced that the company has been awarded a National Heart, Lung and Blood Institute Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The grant enables OrPro to advance development of its lead product, ORP-100, for the treatment of cystic fibrosis (CF), an inherited genetic disease that affects approximately 80,000 people worldwide.

"This award focuses on an inhaled formulation of ORP-100 for topical delivery to the lung surface, a key milestone in our preclinical development program," said Peter B. Heifetz, Ph.D., OrPro president and chief technology officer. "NIH grants are highly competitive, and our proposal received excellent reviews and scores acknowledging OrPro's strong team and innovative approach to CF therapy."

ORP-100 is a recombinant engineered variant of thioredoxin, a human lung protein that has demonstrated in laboratory studies a potent ability to increase the fluidity of mucus. Clearance of the thickened mucus that is characteristic of CF remains a central and poorly met treatment objective. ORP-100 will be administered through an advanced aerosol delivery system, and in contrast to DNA-degrading mucolytics, targets the adhesive protein gel network that is common to all patients with obstructive mucus.

"We are excited about the potential for ORP-100 to be a next-generation mucus-thinning (mucolytic) drug that will offer a convenient, safe and effective treatment alternative to the people who suffer from CF," said Jeff Raser, chief operating officer.  "New therapeutic strategies to correct underlying CF defects have promise, but there still remains a critical need for superior mucolytic therapies in CF and other obstructive pulmonary diseases such as bronchiectasis."

The mucolytic properties of thioredoxin were discovered at leading respiratory hospital National Jewish Health (NJH) in Denver, CO by pediatric pulmonologist Dr. Carl White, M.D.  In 2011, OrPro licensed from NJH an intellectual property portfolio claiming compositions and uses of the thioredoxin active site for the treatment of pulmonary disease.  Dr. White (now at University of Colorado Denver/Children's Hospital Colorado), and his NJH colleague Dr. David Nichols are medical advisors to the company, and will collaborate on the NIH-funded project. 

"We have assembled a world-class team of experts in research, preclinical/clinical development, biologics manufacturing, and finance to help guide OrPro in the development of this exciting new product candidate," said Heifetz, who is also principal investigator on the SBIR grant. "We believe the support from NIH will act as a catalyst for the company and we look forward to completing an initial round of financing to accelerate our development efforts."

About OrPro

OrPro Therapeutics, Inc. is a pre-clinical stage biopharmaceutical company headquartered in San Diego, CA. The company's goal is to develop a breakthrough class of safe, well-tolerated and more effective inhaled non-systemic drugs based on the thioredoxin active site for the treatment of patients with cystic fibrosis (CF), COPD/emphysema, bronchiectasis, severe asthma, and other serious obstructive pulmonary diseases. These diseases are characterized by thickened mucus resulting in impaired lung function. Poor clearance of abnormal, sticky mucus is associated with chronic infection and premature death, especially in CF. Despite advances in antibiotic therapy and other treatments there remains a large unmet medical need for improved mucus-reducing (mucolytic) drugs which in many cases are the most efficacious means of mitigating disease symptoms. Effective new treatments for CF are forecast to achieve peak annual sales in excess of $1 billion annually. OrPro's lead product, ORP-100, an aerosolized variant of recombinant human thioredoxin, will target abnormal viscosity due to excess protein gels in CF and has the potential for broader clinical efficacy than existing mucolytic approaches. 

About National Jewish Health

National Jewish Health is known worldwide for treatment of patients with respiratory, cardiac, immune and related disorders, and for groundbreaking medical research. Founded in 1899 as a nonprofit hospital, National Jewish Health remains the only facility in the world dedicated exclusively to these disorders. Since 1998, U.S. News & World Report has ranked National Jewish the #1 respiratory hospital in the nation.


Michele Parisi
for OrPro Therapeutics

Jeff Raser
OrPro Therapeutics

SOURCE OrPro Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics Announces Institutional Investor Purchased Additional $15 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock
2. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
3. Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers
4. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
5. PTC Therapeutics Closes $30 Million Financing
6. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
7. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
8. Echo Therapeutics Expands License Agreement with Ferndale Pharma
9. PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
10. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
11. NIPTE Will Participate in NIHs Therapeutics for Rare and Neglected Diseases (TRND) Program
Post Your Comments:
(Date:11/25/2015)... -- The total global healthcare industry is expected to grow at ... America has the highest projected growth at 12.7%, ... ), is second with growth projected at 11.5%. ... expenditure. In 2013-2014, total government funded healthcare was nearly 68%. ... 41.2% in 2013-2014. In real terms, out of pocket expenditure ...
(Date:11/25/2015)... WOODBURY, N.Y. , Nov. 25, 2015  Linden ... access and optimizing treatment outcomes for patients suffering from ... its request for a Temporary Restraining Order (TRO) enjoining ... between the two companies. --> ... aggressively pursuing all of its legal options. ...
(Date:11/25/2015)... USA , Inc., a leader in ... accuracy of its blood glucose meter systems. Last week ... Cardiovascular Disease in Los Angeles , ... 01 meter and the Assure ® Prism multi-user ... measure glucose levels in blood is essential for people ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., the ... 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted by the ... Wednesday, November 11th, 2015. The conference was held at the Hawaii Convention Center ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... mental health and wellness consultation, has collaborated with Women’s Web – an ... reader’s queries on topics on mental and emotional well-being relationship, life balance, ...
(Date:11/25/2015)... Ill. (PRWEB) , ... November 25, 2015 , ... ... and potentially more aggressive than those found on mammography, according to a study ... findings of additional cancers not seen on mammography may necessitate a change in ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... gatherings where preparing the perfect dish and pleasing the palates of attendees is ... or bringing a dish to a seasonal get-together, give these recipes a try ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... companies, has been recognized once again for its stellar workplace culture with the ... Work.” , Medical Solutions’ Cincinnati office was named a finalist in ...
Breaking Medicine News(10 mins):